Use of single donor platelets

Kirkley, Scott A.

doi:10.1016/0268-960x(94)90074-r

Cited by 22 publications

(8 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The impact of PC storage on post-transfusion platelet increment has been evaluated in several studies [5,6]. It has been assumed that SD-PC are superior to RDP regarding corrected count increments (CCI) after transfusion [7], but this subject remains questionable [8].…”

Section: Introductionmentioning

confidence: 99%

In-vivo evaluation of random donor platelet concentrates from pooled buffy coats

Klüter

Dörges

Maaß

et al. 1996

Annals of Hematology

View full text Add to dashboard Cite

Random-donor platelet concentrates (PC) prepared from pooled buffy coats have recently been described as an alternative method for platelet preparation. We evaluated such PCs in the clinical setting compared with a standard PC from platelet apheresis. PCs were prepared either from pools of buffy coats (BC-PC) or from single donors (SD-PC) with the cell separator CS-3000 plus. PCs were stored for up to 5 days before transfusion. We compared fresh PC (day 1) with stored (day 2-3) and long-stored PC (day 4-5). For analysis, platelet increment in the recipient was determined immediately and 16-22 h (mean 20 h) after transfusion, corrected for total body area and transfused platelets (CCI). A total of 316 PCs were administered to 36 thrombocytopenic patients suffering from various hematological disorders. Patients with detectable HLA or platelet-specific antibodies or splenomegaly were excluded from the study. Mean platelet content of the PC was 262 x 10(9) for BC-PC and 251 x 10(9) for SD-PC. The 20-h CCI after transfusion of fresh PC was slightly higher with BC-PC than with SD-PC (14.5 versus 11.9; p = 0.19), but values did not differ significantly between the two types of PC on any day of storage. For BC-PC, 20-h CCI decreased with further storage by 30% (10.2; p = 0.02). For SD-PC a decrease by 9% was not significant. In conclusion, platelet concentrates prepared from pools of buffy coats showed excellent transfusion results when administered fresh, but storage decreased the CCI by 30%. No significant difference from PCs from plateletpheresis was observed on any day of storage. Both types of platelet concentrates were capable of sufficient platelet increment even when stored for up to 5 days.

show abstract

Section: Introductionmentioning

confidence: 99%

In-vivo evaluation of random donor platelet concentrates from pooled buffy coats

Klüter

Dörges

Maaß

et al. 1996

Annals of Hematology

View full text Add to dashboard Cite

show abstract

“…There are some reasonable advantages to single donor platelets including reduced disease transmission, reduced alloimmunization, superior function, and storage characteristics (16). Moreover, an equivalent dose of manual PCs requires at least 4–6 donors every time with increased alloimmunization, which is likely to cause platelet transfusion refractoriness (PTR).…”

Section: Discussionmentioning

confidence: 99%

Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients

et al. 2017

View full text Add to dashboard Cite

The aim of the present study was to evaluate the clinical efficacy between manual buffy coat-derived platelet concentrates (PCs) and automated apheresis platelet concentrates (APCs) in terms of their therapeutic effects. The corrected count increment (CCI) was calculated according to detected differences in platelet concentration in patients who underwent transfusion of APCs, prepared by an automated system (group I, 72 cases) or PCs derived from buffy coat by manual method (group II, 83 cases). The clinical efficacy was assessed in terms of the CCI and clinical symptoms. The platelet contents of all the PCs were detected before transfusion. The mean 1 h CCI was 13.56±4.45 and 24 h CCI was 8.67±4.21 in group I, while the mean 1 h CCI was 15.83±4.65 and 24 h CCI was 9.57±3.36 in group II. The effective rates judged by CCI for groups I and II were 53 and 64%, respectively, and those judged by clinical symptoms were 67 and 60%, respectively. In conclusion, the clinical effectiveness of manual PCs was similar to that for APCs; thus, it could be utilized for clinical use.

show abstract

“…4,27 Un nuevo panorama: donante único Este término abarca no sólo a los voluntarios que donan parte de su contenido hemático y que, posteriormente, se almacena o procesa de acuerdo con las necesidades, sino que también incluye a la medicina transfusional, que consta de la inmunoterapia, la terapia celular y de tejidos. 28,29 Se entiende por donante único a la transfusión alogénica de las células sanguíneas provenientes de un solo individuo, con lo que disminuye el riesgo de complicaciones debido a situaciones de incompatibilidad. 30 En un estudio efectuado por Strauss y su grupo 30 se consiguió determinar, en una población pediátrica, que la modalidad de donante único debe considerarse en pacientes con cirugía electiva y con necesidad anticipada de glóbulos rojos.…”

Section: Complicaciones De Las Transfusionesunclassified

Requerimiento de paquetes eritrocitarios en neonatos: una revisión cualitativa

et al. 2018

View full text Add to dashboard Cite

ANTECEDENTES: La trasfusión de hemoderivados, sobre todo de glóbulos rojos, es una de las intervenciones más comunes en la práctica médica diaria. En las unidades de neonatología la población objetivo de esta intervención suelen ser recién nacidos pretérmino, en particular los de alto riesgo con prematurez extrema y con bajo peso al nacer.OBJETIVO: Exponer los aspectos más relevantes de la indicación de hemoderivados a neonatos y la evidencia disponible al respecto: indicaciones, complicaciones, aspectos técnicos y medidas para reducir los riesgos asociados con el procedimiento, como las alícuotas de donante único.DESCRIPCIÓN: Las transfusiones de productos sanguíneos a los neonatos son un procedimiento asociado con múltiples desenlaces desfavorables, como: enterocolitis necrosante, retinopatía del prematuro, hemorragia intraventricular, enfermedad pulmonar crónica, entre otros. La decisión de efectuar este procedimiento debe tomarse con base en las indicaciones establecidas y las posibles complicaciones.CONCLUSIONES: El uso de alícuotas de donante único es uno de los nuevos desarrollos dirigido a disminuir los riesgos asociados y las complicaciones de incompatibilidad.

show abstract

Use of single donor platelets

Cited by 22 publications

References 46 publications

In-vivo evaluation of random donor platelet concentrates from pooled buffy coats

In-vivo evaluation of random donor platelet concentrates from pooled buffy coats

Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients

Requerimiento de paquetes eritrocitarios en neonatos: una revisión cualitativa

Contact Info

Product

Resources

About